January - 2019

MECFA Blog

Personalized Nutrition Programs May Help Improve Outcomes for CF Patients, Survey Suggests

New personalized strategies that can address the nutritional needs of cystic fibrosis patients may provide the best care and improve...

The Diverse Spectrum of Health Across the CF Community

If you’ve ever met more than one person with cystic fibrosis, it’s likely they had very different experiences than you. First, their...

At-home DNA test kits: Medical experts warn buyers beware

(WRIC) - Did you or someone you know get an at-home DNA test kit for Christmas? They were one of the hottest holiday items. It's an easy...

Non-invasive Ventilation Improves Lung Function in CF Patients But Not Survival, Study Finds

A reassessment of U.K. medical records showed that in cystic fibrosis (CF) patients, breathing support provided by gas inhalation,...

Cystic fibrosis drug combo found safe and effective for 2–5 year olds

An open label phase 3 study conducted at Ann & Robert H. Lurie Children’s Hospital of Chicago and other centers established that a...

Eluforsen Improves CFTR Protein Function in CF Patients with F508del Mutations, Phase 1 Trial Shows

An exploratory Phase 1 trial showed that repeated intranasal treatment with the therapy eluforsen improved CFTR protein activity in...

WHO Approves Ensifentrine as Name for Potential Inhaled Treatment Now in Clinical Trials

The World Health Organization (WHO) approved ensifentrine as the recommended name to identify the cystic fibrosis (CF) treatment...

Bacterial immunity and infectious disease

Patients with cystic fibrosis are often infected by pseudomonas aeruginosa, a bacterium that infects the lungs and prevents breathing,...

Inhalable RNA could breathe new life into lung cancer treatments

Lung epithelial cells that have taken up the mRNA particles (yellow dots), which makes them glow green(Credit: Asha Patel) In the body,...

Online Program Educates Clinicians Treating MS About Common Comorbidities & Current & New Tr

(MENAFN - PRLog) eMultipleSclerosis Review® Volume 2 launches with new design eMultipleSclerosis Review Spread the Word Listed Under Tag:...

Disease Duration, Flare-ups Affect Mental Health of Non-CF Bronchiectasis Patients, Study Finds

VERTEX’S CF BLOCKBUSTER TRIKAFTA EFFECTIVE IN KIDS 6 TO 11 YEARS OF AGE

A case for improved carrier screening

Vertex to Seek Expanded FDA Approval for Trikafta After Positive Child Safety Data

Vertex’s Kaftrio approved for use in Europe and made accessible on the NHS

Age May Affect Outcomes in Lung Transplant Recipients With Cystic Fibrosis

CFF Funding Will Further ContraFect’s Research Into Alternative for Antibiotics

The search for molecular glue in targeted disease control

Vest Therapy Lowers Risk of Hospitalization in Non-CF Bronchiectasis, Study Says

Harvard is working with Boston hospitals to test existing cystic fibrosis drug to help coronavirus p